Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Laryngoscope. 2021 Jan 12;131(7):E2125–E2130. doi: 10.1002/lary.29385

Fig. 3.

Fig. 3.

DON treatment reduced Col1a1, Col3a1, Col5a1, and Tgfβ expression in iLTS mice. (A). At day 7, DON treatment significantly decreased the expression of Cola1, Col3a1, Col5a1 and Tgfβ and increased αSma expression in iLTS mice compared to PBS group. Fn expression did not change after DON treatment at day 7. (B) At day 14, expression of Cola1, Col3a1, and Tgfβ were decreased after DON treatment in iLTS mice. Col5a1 and αSma expression did not change. (*) = P < .05; (**) = P < .01. DON: 6-Diazo-5-oxo-L-norleucine; Colla1: collagen 1; Col3a1: collagen 3; Col5a1 collagen 5; αSma: alpha-smooth muscle actin; Tgfβ: transforming growth factor-beta; Fn: fibronectin.